A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 6, 2025

Primary Completion Date

July 15, 2025

Study Completion Date

July 22, 2025

Conditions

Hyperphosphatemia Patients on Hemodialysis

Interventions

DRUG

TS-172

oral administration of TS-172 20\~60 mg/day

DRUG

Placebo

oral administration of placebo

Trial Locations (1)

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors

lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT06745518 - A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders | Biotech Hunter | Biotech Hunter